Patents by Inventor Thomas Friess

Thomas Friess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR
    Publication number: 20240139192
    Abstract: The present invention is directed to the combination therapy of cancer with a BRAF inhibitor and a MEK inhibitor, as well as uses and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 8, 2023
    Publication date: May 2, 2024
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Jan ECKMANN, Thomas FRIESS, Frank HERTING, Yusuke IDE, Hiroshi TANAKA, Piergiorgio Francesco Tommaso PETTAZZONI, Juergen WICHMANN
  • COMBINATION THERAPY WITH A BET INHIBITOR AND A PROTEASOME INHIBITOR
    Publication number: 20210023099
    Abstract: The present invention is directed to the combination therapy, in particular of multiple myeloma, with a BET inhibitor and a proteasome inhibitor.
    Type: Application
    Filed: October 15, 2020
    Publication date: January 28, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mark D. Demario, Thomas Friess, Astrid Alexandra Ruefli-Brasse
  • COMBINATION THERAPY WITH A BET INHIBITOR AND A BCL-2 INHIBITOR
    Publication number: 20200237779
    Abstract: The present invention is directed to the combination therapy of multiple myeloma with a BET inhibitor and a Bcl-2 inhibitor.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mark D. DEMARIO, Thomas FRIESS, Astrid Alexandra RUEFLI-BRASSE
  • COMBINATION THERAPY WITH A BET INHIBITOR, A BCL-2 INHIBITOR AND AN ANTI-CD20 ANTIBODY
    Publication number: 20200237905
    Abstract: The present invention is directed to the combination therapy of DLBCL with a BET inhibitor, a Bcl-2 inhibitor and an anti-CD20 antibody.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mark D. DEMARIO, Thomas FRIESS, Astrid Alexandra RUEFLI-BRASSE
  • ANTI-TPBG ANTIBODIES AND METHODS OF USE
    Publication number: 20200108154
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Application
    Filed: August 28, 2019
    Publication date: April 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jen FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
  • Anti-TPBG antibodies and methods of use
    Patent number: 10434184
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Jens Fischer, Thomas Friess, Sabine Imhof-Jung, Ben-Fillippo Krippendorff, Christian Schantz, Tilman Schlothauer, Claudio Sustmann, Barbara Weiser, Adrian Zwick
  • Anti-HER3 antibodies and uses thereof
    Patent number: 10196456
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: February 5, 2019
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • ANTI-TPBG ANTIBODIES AND METHODS OF USE
    Publication number: 20180311371
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
  • TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY
    Publication number: 20180251536
    Abstract: The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.
    Type: Application
    Filed: October 23, 2017
    Publication date: September 6, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Max Hasmann, Werner Scheuer
  • COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS
    Publication number: 20180064808
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, and in particular to combination therapies employing such bispecific antibodies and a chemotherapeutic agent, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: April 7, 2017
    Publication date: March 8, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Oliver Krieter, Meher Majety, Katharina Wartha
  • TUMOR THERAPY WITH AN ANTIBODY FOR VASCULAR ENDOTHELIAL GROWTH FACTOR AND AN ANTIBODY FOR HUMAN EPITHELIAL GROWTH FACTOR RECEPTOR TYPE 2
    Publication number: 20170239353
    Abstract: The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
    Type: Application
    Filed: May 10, 2017
    Publication date: August 24, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Max Hasmann, Werner Scheuer
  • ANTI-HER3 ANTIBODIES AND USES THEREOF
    Publication number: 20170174784
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 22, 2017
    Applicant: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Anti-HER3 antibodies and uses thereof
    Patent number: 9611331
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES
    Publication number: 20160159912
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Application
    Filed: October 7, 2015
    Publication date: June 9, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR
    Publication number: 20160000912
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a proteasome inhibitor for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and a proteasome inhibitor. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and a proteasome inhibitor. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and a proteasome inhibitor.
    Type: Application
    Filed: June 16, 2014
    Publication date: January 7, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: GEORG FERTIG, THOMAS FRIESS, CHRISTIAN KLEIN, PABLO UMANA
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC)
    Publication number: 20160000911
    Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
    Type: Application
    Filed: June 5, 2014
    Publication date: January 7, 2016
    Applicant: ROCHE GLYCART AG
    Inventors: CHARLES DUMONTET, THOMAS FRIESS, FRANK HERTING, CHRISTIAN KLEIN, PABLO UMANA
  • Combination therapy of anti-HER3 antibodies
    Patent number: 9180185
    Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 10, 2015
    Assignee: Hoffman-La Roche Inc.
    Inventors: Frieder Bauss, Birgit Bossenmaier, Thomas Friess, Christian Gerdes, Max Hasmann, Marlene Thomas, Martin Weisser
  • Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2
    Publication number: 20150283238
    Abstract: The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 8, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Thomas Friess, Max Hasmann, Werner Scheuer
  • TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY
    Publication number: 20150239969
    Abstract: The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Thomas Friess, Max Hasmann, Werner Scheuer
  • Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
    Patent number: 9090700
    Abstract: The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: July 28, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Friess, Max Hasmann, Werner Scheuer